Latest From Atoll GmbH
Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.
Allergan rebounded from the derailed Pfizer acquisition by signing a $3 billion partnership with Heptares to develop small-molecule muscarinic receptor agonists in CNS diseases; there was a huge consolidation in cardiovascular devices through Abbott's $25 billion purchase of St. Jude Medical. Biopharma funding totaled $1.1 billion, while device fundraising reached $248 million.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Supplies – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2016.
- Synthesis Technologies, Production Processes
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Western Europe
- Company Type
- Midsize European
- Parent & Subsidiaries
- Atoll GmbH
- Senior Management
- Contact Info
Phone: 751 - 56 121 0
Ettishofer Straße 10
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.